Clinical Trials

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

A phase 1 clinical study of NXP900 in patients with advanced cancers

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer